Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

Rhea-AI Summary

Aptinyx Inc. (NASDAQ: APTX) announced a conference call on November 8, 2022, at 5:00 p.m. ET to discuss its third quarter 2022 financial results and recent business highlights. The company focuses on developing therapies for brain and nervous system disorders and is advancing clinical development of two product candidates addressing cognitive impairment and post-traumatic stress disorder. A live audio webcast will be available on Aptinyx's website.

Positive

• Aptinyx is advancing two product candidates in clinical development for cognitive impairment and PTSD.
• The company has a unique NMDA receptor modulation platform, potentially leading to innovative treatments.

Negative

• None.

EVANSTON, Ill.--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights.

To access the live conference call, please dial 844-200-6205 (domestic) or 929-526-1599 (international) and refer to conference ID 141144. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx’s website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has two product candidates in clinical development in central nervous system indications, including cognitive impairment and post-traumatic stress disorder. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221018005503/en/

Investor & Media Contact:

Patrick Flavin

Aptinyx Inc.

ir@aptinyx.com or corporate@aptinyx.com

847-871-0377

Source: Aptinyx Inc.

FAQ

When will Aptinyx report its third quarter 2022 financial results?

Aptinyx will report its third quarter 2022 financial results on November 8, 2022.

How can I access the Aptinyx conference call?

You can dial 844-200-6205 for domestic access or 929-526-1599 for international access, using conference ID 141144.

What is Aptinyx's focus in drug development?

Aptinyx focuses on developing therapies for brain and nervous system disorders, particularly through NMDA receptor modulation.

What are the key product candidates of Aptinyx?

Aptinyx has two product candidates in clinical development targeting cognitive impairment and post-traumatic stress disorder.